Article Details
Retrieved on: 2024-10-27 20:38:16
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses the FDA-approved microbiome-based therapy, live-jslm (Rebyota), for preventing recurrent *Clostridioides difficile* infections, focusing on real-world clinical trial data presented in Philadelphia. SEO relates indirectly through standard optimization practices for health-related content.
Article found on: www.hcplive.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here